Cellectricon Announces Record Q1 Sales20 April 2006
Cellectricon, a leading provider of cell-based screening solutions, today announced record sales for the first quarter 2006. The sales increased by 160% compared to the first quarter 2005 making it the company's best sales result ever.
"We are very pleased with achieving the best sales results ever," commented Dr. Mattias Karlsson, Chief Operating Officer. "We've continued to attract new top-reference customers and experience a growing demand for our micro-scale and cell-based screening systems for drug discovery. The market acceptance for our products is gratifying and our R&D efforts continue to accelerate with several new products in the pipeline scheduled for release later this year and during 2007. We will aggressively address several high growth markets within cell biology and develop innovative solutions for our customers within segments such as cell-based screening, transfection and biomedical research."
The following business developments and sales were significant in the first quarter:
- Record sales of the Dynaflow System a screening and lead optimisation
tool for drugs acting on ion channel receptors and safety pharmacology
testing. The microfluidic-chip based system is now being used
routinely in numerous key locations and has strong customer
validation from 10 of the world's top 12 pharmaceutical companies.
- A breakthrough order for the newly launched Cellaxess System.
Commenting on the order, Professor Hakan Westerblad, Dept. of
Physiology and Pharmacology, Karolinska Institutet, said, "Thanks to
the unique features of the Cellaxess system we are very pleased to
incorporate the technology into our research. Since Cellaxess enables
electroporation of hard-to-transfect cell types we can now introduce
large molecules (proteins, RNA etc) into adult mouse skeletal muscle
cells without causing any noticeable damage."
- Microfabrication Service - Cellectricon's new business unit offering
the company's unique development expertise and in-house facility for
microfabrication. Cellectricon has signed an agreement with Nanoxis AB
(www.nanoxis.com) to manufacture their new membrane protein chip.
About Cellectricon
Cellectricon AB (Gothenburg, Sweden) invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilises state of the art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products are designed to enable substantial increases in productivity at the highest data quality. The company was formed in 2000 based on an extensive and solid patent portfolio within different areas such as high-throughput electrophysiology, microfluidics, microfabrication, and electroporation.
For further information: Susanne Fagerlund, Communications Manager, Phone: +46-31-760-35-15, susanne.fagerlund@cellectricon.com
Source: newswire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
